- Home
- ACRV vs KFS Comparison
ACRV vs KFS Comparison
Compare ACRV & KFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- KFS
- Stock Information
- Founded
- ACRV 2018
- KFS 1989
- Country
- ACRV United States
- KFS United States
- Employees
- ACRV N/A
- KFS N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- KFS Property-Casualty Insurers
- Sector
- ACRV Health Care
- KFS Finance
- Exchange
- ACRV Nasdaq
- KFS Nasdaq
- Market Cap
- ACRV 247.8M
- KFS 234.2M
- IPO Year
- ACRV 2022
- KFS 1996
- Fundamental
- Price
- ACRV $7.93
- KFS $8.91
- Analyst Decision
- ACRV Strong Buy
- KFS
- Analyst Count
- ACRV 5
- KFS 0
- Target Price
- ACRV $22.60
- KFS N/A
- AVG Volume (30 Days)
- ACRV 44.0K
- KFS 32.6K
- Earning Date
- ACRV 11-13-2024
- KFS 11-06-2024
- Dividend Yield
- ACRV N/A
- KFS N/A
- EPS Growth
- ACRV N/A
- KFS N/A
- EPS
- ACRV N/A
- KFS N/A
- Revenue
- ACRV N/A
- KFS $108,627,000.00
- Revenue This Year
- ACRV N/A
- KFS N/A
- Revenue Next Year
- ACRV N/A
- KFS N/A
- P/E Ratio
- ACRV N/A
- KFS N/A
- Revenue Growth
- ACRV N/A
- KFS 2.02
- 52 Week Low
- ACRV $3.19
- KFS $6.85
- 52 Week High
- ACRV $11.90
- KFS $9.58
- Technical
- Relative Strength Index (RSI)
- ACRV 48.40
- KFS 48.80
- Support Level
- ACRV $7.69
- KFS $8.65
- Resistance Level
- ACRV $8.66
- KFS $9.58
- Average True Range (ATR)
- ACRV 0.34
- KFS 0.32
- MACD
- ACRV -0.00
- KFS -0.07
- Stochastic Oscillator
- ACRV 22.64
- KFS 27.42
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.